The IV delivery of an AAV9 based gene replacement therapy using the Mecp2 knockout model of Rett syndrome improved survival in the treated cohort compared to the untreated Mecp2-null mice, despite relatively low levels of neuronal transduction (2–4%) [95]. Here, MECP2 is linked to Rett syndrome.